Epithelial ovarian cancer: Focus on targeted therapy

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 1, 2011, Pages 17-23

  Pliarchopoulou, Kyriaki ^a   Pectasides, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Ovarian cancer; Targeted therapy; Treatment strategies

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FARLETUZUMAB; FOLATE RECEPTOR 1; GEFITINIB; IMATINIB; MATUZUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPITHELIAL OVARIAN CANCER; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LOW DRUG DOSE; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957936164     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.004     Document Type: Review

References (64)

1. http://www.cancer.org/.
2. Dinh P., Harnett P., Piccart-Gebhart M.J., et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 2008, 67:103-112.
3. Hicklin D.J., Ellis L.M. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
4. Ramakrishnan S., Subramanian I.V., Yokoyama Y., et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005, 8:169-182.
5. Martin L., Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007, 25:2894-2901.
6. Raspollini M.R., Amunni G., Villanucci A., et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004, 14:815-823.
7. Hu L., Hoffmann J., Zaloudak C., et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002, 161:1917-1924.
8. Tran J., Master Z., Yu J.L., et al. A role of survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002, 99:4349-4354.
9. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153:1249-1256.
10. Burger R.A., Sill M.W., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
11. Cannistra S.A., Matulonis S.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
12. Burger R.A., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group Study. LBA1 abstract, 46th ASCO Annual Meeting 2010.
13. Tew W.P., Colombo N., Ray-Coquard I., et al. VEGF-trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized, multicenter phase II study. ASCO Meeting Abstracts 2007, 5508.
14. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82.
15. McGonigle K.F., Muntz H.G., Vuky J.L., et al. A phase II prospective study of weekly topotecan and bevacizumab in platinum-refractory ovarian and peritoneal cancer. ASCO Meeting Abstracts 2008, 5551.
16. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. A phase II study of outpatients first-line paclitaxel, carboplatin and bevacizumab for advanced-stage epithelial ovarian, peritoneal and fallopian tube cancer. Int J Gynecol Cancer 2007, 17:771-776.
17. Campos S.M., Dizon D.S., Cannistra S.A., et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. ASCO Meeting Abstracts 2007, 5517.
18. Biagi J.J., Oza A.M., Grimshaw R., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. ASCO Meeting Abstracts 2008, 5522.
19. Matei D., Sill M.W., De Geest K., et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008, 26:5537.
20. Welch S., Hirte H., Schilder R.J., et al. Phase II study of sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. Proc Am Soc Clin Oncol 2006, 24(18s):5084a.
21. Welch S., Hirte H., Elit R., et al. Ca125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-a trial of the PMH phase II consortium. Proc Am Soc Clin Oncol 2007, 25(18s):5519a.
22. Friedlander M., Hancock K.C., Rischin D., et al. Pazopanib is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J Clin Oncol 2007, 25:5561.
23. Matulonis U., Berlin S., Ivy P., et al. Cetiranib is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2008, 26:5501.
24. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib in recurrent or persistent ovarian, peritoneal of fallopian tube cancer: final results of PMH, Chicago and California consortia trial. ASCO Meeting Abstracts 2008, 5521.
25. Ciardello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005, 1(2):221-234.
26. Bartlett J.M., Langdon S.P., Simpson B.J., et al. The prognostic value of epidermal growth factor receptor m-RNA expression in primary ovarian cancer. Br J Cancer 1996, 73:301-306.
27. Sirotnak F.M. Studies with ZD1839 in preclinical models. Semin Oncol 2003, 30:12-20.
28. Schilder R.J., Sill M.W., Chen X., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005, 11:5539-5548.
29. Slomowitz B.M., Coleman R.L., Levenback C., et al. Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal or fallopian tube cancer. Proc Am Soc Clin Oncol 2006, 24(18s):5090a.
30. Pautier P., Jolly F., Kerbrat P., et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: final results of a phase II study. ASCO Meeting Abstracts 2007, 5566.
31. Wagner U., du Bois A., Pfisterer J., et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group. Gynecol Oncol 2007, 105(1):132-137.
32. Gordon N.A., Finkler N., Edwards R.P., et al. Efficacy and safety of erlotinib, an epidermal growth factor tyrosine kinase inhibitor in patients with advanced ovarian carcinoma: results from a phase II multicentre study. Int J Gynecol Cancer 2005, 15:785-792.
33. Blank S.V., Curtin J.P., Goldman N.A., et al. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. Proc Am Soc Clin Oncol 2006, 24:5076.
34. Vasey P.L., Paul J., Rustin R., et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008, 98:1774-1780.
35. Vasey P.A., Paul J., Rustin R., et al. Maintenance erlotinib following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian cancer. Proc Am Soc Clin Oncol 2007, 25:5560a.
36. Campos S., Hamid O., Seiden M.V., et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005, 23:5597-5604.
37. Schilder R.J., Lokshin A.E., Holloway R.W., et al. Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose-escalation to rash. Proc Am Soc Clin Oncol 2007, 25:5577a.
38. Secord A.A., Blessing J.A., Armstrong D.K., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 108:493-499.
39. Konner J., Schilder R.J., DeRosa F.A., et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal or fallopian tube cancer. Gynecol Oncol 2008, 110:140-145.
40. Seiden M., Burris H.A., Matulonis U., et al. A phase II trial of EMD72000, a humanized anti-EGFR monoclonal antibody in subjects with heavily pretreated and platinum-resistant advanced mullerian malignancies. Gynecol Oncol 2007, 104(3):727-731.
41. Bookman M.A., Darcy K.M., Clarke-Pearson D., et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290.
42. Gordon M.S., Matei D., Aghajanian C., et al. Clinical activity of pertuzumab, a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006, 24:4324-4332.
43. Amler L., Makhija S., Januario T., et al. HER pathway gene expression analysis in a phase II study of pertuzumab plus gemcitabine vs gemcitabine and placebo in patients with platinum-resistant epithelial ovarian cancer. ASCO Meeting Abstracts 2008, 5552.
44. Kaye S.B., Poole C.J., Bidzinski M., et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab vs carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. ASCO Meeting Abstracts 2008, 5520.
45. Rivkin S.E., Muller C., Iriarte D., et al. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. ASCO Meeting Abstracts 2008, 5556.
46. Henriksen R., Funa K., Wilander E., et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993, 53:4550-4554.
47. Coleman R.L., Broaddus R.R., Bodurka D.C., et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006, 101:126-131.
48. Matei D., Emerson R.E., Schilder J., et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008, 113:723-732.
49. Nimeiri H.S., Oza A.M., Morgan R.J., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal and fallopian tube cancer: a trial of the Chicago, PMH and California Phase II consortia. Gynecol Oncol 2008, 110:49-55.
50. Azad N.S., Posadas E.M., Kwitowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
51. Nathan P., Judson I., Padhani A., et al. A phase I study of combretastatin A4 phosphate and bevacizumab in subjects with advanced solid tumors. ASCO Meeting Abstracts 2008, 3418-3425.
52. Kally K.R., Oberg A.L., Keeney G.L., et al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008, 108:619-626.
53. Armstrong D., Bicher A., Coleman R.L., et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor α, in platinum-sensitive ovarian cancer in first relapse. ASCO Meeting Abstracts 2008, 5500.
54. Gundmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic instability. Oncogene 2006, 25:5864-5874.
55. Fong P.C., Boss D.S., Carden C.P., et al. AZD2281, a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. ASCO Meeting Abstracts 2008, 5510.
56. Turner N., Tutt A., Ashworth A. Hallmarks of " BRCAness" in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
57. Altomare D.A., Wang H.Q., Skele K.L., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23(24):5853-5857.
58. Lopiccolo J., Blumenthal G.M., Bernstein W.B., et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50.
59. Chen T., George G.A., Taylor C.C. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?. Anti-cancer Drugs 2006, 17(2):123-131.
60. Klampfel L. Signal transducers and activators of transcription (STATs): novel targets for chemopreventative and chemotherapeutic drugs. Curr Cancer Drug Targets 2006, 6(2):107-121.
61. Mc Phillips F., Mullen P., Macleod K.G., et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006, 27(4):729-739.
62. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 2004, 4(2):125-146.
63. Fu S., Hu W., Kavanagh J.J., et al. Targeting aurora kinases in ovarian cancer. Expert Opin Ther Targets 2006, 10(1):77-85.
64. Kamat A.A., Fletcher M., Gruman L.M., et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006, 12(6):1707-1714.